#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinal dystrophy Autoinflammation with infantile enterocolitis Cryoglobulinaemia Chronic myeloid leukaemia Choroid melanoma Bone marrow disorder Anal cancer Craniocerebral injury Plasma cell myeloma refractory Alagille syndrome B-cell type acute leukaemia Small intestine adenocarcinoma Malignant central nervous system neoplasm Renal cancer metastatic Bronchopulmonary dysplasia More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I – Treatment Hereditary motor and sensory neuropathy – Basic Information Shprintzen-Goldberg syndrome – Trials in Disease Hepatoblastoma – Life with Disease Anaplastic thyroid cancer – Basic Information Mucous membrane pemphigoid Pemphigus – Diagnostics Methylmalonic acidaemia – Treatment Thrombotic thrombocytopenic purpura – Trials in Disease Factor VIII deficiency – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LY3537021 R2R01 Lasofoxifene Pembrolizumab Mifamurtide NAVENIBART Human Serum Albumin Atropine Sulfate Monohydrate Altizide Maraviroc Cannabidiol Interleukin-2 Sarilumab Neostigmine Methylsulfate Vortioxetine Hydrobromide Isoflurane VAMIFEPORT TRIHYDROCHLORIDE Regn9933 Quercus Ilex Allergen Extract Vortioxetine More therapies…

    Learn about Your Condition

    Osteomyelitis Injection site pain Colon cancer stage II Neutropenia Anxiety disorder Eczema Neuropathy peripheral Rett syndrome CADASIL Androgenetic alopecia Hepatic encephalopathy Clinically isolated syndrome Autoimmune hepatitis Ataxia telangiectasia Triple negative breast cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Juvenile idiopathic arthritis

  • A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Filgotinib
    Belgium Bulgaria Czechia France Germany Greece +4

  • A study to evaluate the safety and effectiveness of filgotinib in children and adolescents with juvenile idiopathic arthritis.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Filgotinib
    France Germany

  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria Czechia Germany Italy Romania Spain

  • Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Sarilumab
    Bulgaria Finland France Germany Greece Hungary +5

  • Study on Treatment Strategies for Children and Adolescents with Juvenile Idiopathic Arthritis Using Methotrexate and Drug Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Golimumab
    • Adalimumab
    • Etanercept
    Norway

  • Study Comparing Step-up and Step-down Treatment Strategies with Methotrexate and Etanercept for Children with Juvenile Idiopathic Arthritis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Etanercept
    • Methotrexate
    Italy
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!